Xtrackers Europe Market Leaders ETF
XEML - ETF AI Analysis
Top Page
Xtrackers Europe Market Leaders ETF (XEML)
XEML, the Xtrackers Europe Market Leaders ETF, has a solid overall rating driven mainly by high-quality European blue-chip companies with strong financial performance and stability. Major holdings like AstraZeneca, Novartis, and Nestlé support the fund’s quality through robust profitability, healthy cash flows, and generally positive outlooks, while names such as EssilorLuxottica and Inditex add growth but come with valuation and overbought concerns that slightly weigh on the rating. The main risk factor is the ETF’s heavy tilt toward large European healthcare and consumer names, which can expose investors to sector-specific and regional market swings.
XEML vs. SPDR S&P 500 ETF (SPY)
- AUM
- 5.16M
- Region
- Europe
- Expense Ratio
- 0.35%
- Beta
- 0.67
- Issuer
- Xtrackers
- Inception Date
- Dec 23, 2025
- Dividend Yield
- 1.93%
- Asset Class
- Equity
- Index Tracked
- STOXX Europe Total Market Leaders Index - USD - Benchmark TR Net
XEML Summary
Xtrackers Europe Market Leaders ETF (XEML) is a fund that follows the STOXX Europe Total Market Leaders Index, focusing on 40 of Europe’s biggest and strongest companies. It spreads your money across major European markets like France, Switzerland, and the UK, with a tilt toward health care and large general businesses. Well-known holdings include ASML Holding and Novartis. Someone might invest in XEML to get simple, broad exposure to leading European companies in one investment, aiming for long-term growth and diversification. A key risk is that the value can go up or down with the European stock market and large-company performance.
How much will it cost me?
The Xtrackers Europe Market Leaders ETF (XEML) has an expense ratio of 0.35%, which means you’ll pay $3.50 per year for every $1,000 invested. This is slightly higher than average for passively managed ETFs because it focuses on a niche index of Europe's top 40 companies, requiring specialized tracking.
What would affect this ETF?
The XEML ETF, focused on Europe's leading companies, could benefit from positive economic growth in developed Europe, increased consumer spending, and advancements in healthcare and technology sectors, which are heavily represented in its holdings. However, it may face challenges from rising interest rates, regulatory changes in Europe, or economic slowdowns that could impact industrial and consumer-focused companies. Global geopolitical tensions or trade disruptions could also negatively affect its performance.
XEML Top 10 Holdings
XEML is leaning heavily on Europe’s healthcare heavyweights, with names like Novartis, AstraZeneca, Roche, and Sanofi doing much of the lifting as they trend higher and give the fund a defensive backbone. Consumer giants such as L’Oréal and Nestlé add a steady, brand-driven boost, while fashion leader Inditex has been quietly rising in the background. The main drag comes from EssilorLuxottica and Richemont, where recent weakness in luxury is taking some shine off returns. Overall, this is a developed Europe story, not a global one.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 CH:NOVN | Novartis AG | 5.14% | $260.40K | CHF 243.61B | 30.57% | 80Outperform |
 AZN | AstraZeneca | ― | ― | ― | ― | 80Outperform |
 FR:OR | L'Oreal | 5.02% | $254.68K | EUR 239.27B | 26.97% | 71Outperform |
 FR:EL | EssilorLuxottica SA | 5.00% | $253.60K | EUR 89.74B | -38.02% | 68Neutral |
 RHHVF | Roche Holding AG | ― | ― | ― | ― | 73Outperform |
 CH:NESN | Nestlé SA | 4.78% | $242.30K | CHF 220.83B | 8.82% | 71Outperform |
 FR:SAN | Sanofi | 4.69% | $238.01K | EUR 100.45B | -2.18% | 75Outperform |
 GB:GSK | GlaxoSmithKline | 4.60% | $233.15K | GBP 75.77B | 6.27% | 77Outperform |
 ES:ITX | Inditex | 4.53% | $229.93K | EUR 183.76B | 23.77% | 78Outperform |
 CH:CFR | Compagnie Financiere Richemont SA | 4.25% | $215.31K | CHF 99.54B | 8.44% | 78Outperform |
XEML Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XEML, the sentiment is Positive. The current price of 25.37 is above the 20-day moving average (MA) of 24.90, above the 50-day MA of 24.88, and above the 200-day MA of 25.30, indicating a bullish trend. The MACD of 0.21 indicates Negative momentum. The RSI at 56.53 is Neutral, neither overbought nor oversold. The STOCH value of 69.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XEML.
XEML Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| XEML | $25.37 | $28.00(10.38% Upside) | $5.16M | 0.35% | 69Neutral |
 VGK | $87.31 | $103.67(18.73% Upside) | $29.88B | 0.06% | 61Neutral |
 FLEU | $33.87 | $41.13(21.44% Upside) | $69.22M | 0.09% | 62Neutral |
 EUDG | $38.47 | $44.44(15.51% Upside) | $68.86M | 0.58% | 64Neutral |
 DBEZ | $61.16 | $73.86(20.76% Upside) | $68.24M | 0.45% | 61Neutral |
 PTEU | $31.77 | $38.46(21.06% Upside) | $34.16M | 0.65% | 62Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| XEML | Xtrackers Europe Market Leaders ETF | 25.37 | 0.60 | 2.41% | |
| VGK | Vanguard FTSE Europe ETF | 87.31 | 7.95 | 10.01% | |
| FLEU | Franklin FTSE Eurozone ETF | 33.87 | 2.01 | 6.29% | |
| EUDG | WisdomTree Europe Quality Dividend Growth Fund | 38.47 | 3.07 | 8.67% | |
| DBEZ | Xtrackers MSCI Eurozone Hedged Equity ETF | 61.16 | 6.96 | 12.85% | |
| PTEU | Pacer Trendpilot European Index ETF | 31.77 | 1.87 | 6.24% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.